CN209004926U - 供装填干细胞活性胜肽药剂的喉用喷雾器 - Google Patents
供装填干细胞活性胜肽药剂的喉用喷雾器 Download PDFInfo
- Publication number
- CN209004926U CN209004926U CN201721888089.5U CN201721888089U CN209004926U CN 209004926 U CN209004926 U CN 209004926U CN 201721888089 U CN201721888089 U CN 201721888089U CN 209004926 U CN209004926 U CN 209004926U
- Authority
- CN
- China
- Prior art keywords
- stem cell
- suction pipe
- pipe
- victory peptide
- cell activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 67
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 53
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 238000011049 filling Methods 0.000 title claims description 9
- 230000000694 effects Effects 0.000 claims abstract description 45
- 210000000867 larynx Anatomy 0.000 claims abstract description 26
- 238000003825 pressing Methods 0.000 claims description 22
- 230000006835 compression Effects 0.000 claims description 12
- 238000007906 compression Methods 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000000889 atomisation Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 abstract description 7
- 230000004888 barrier function Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920000715 Mucilage Polymers 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- -1 corrigent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000002444 unipotent stem cell Anatomy 0.000 description 2
- RYDFXSRVZBYYJV-TYYBGVCCSA-N (e)-but-2-enedioic acid;sodium Chemical compound [Na].OC(=O)\C=C\C(O)=O RYDFXSRVZBYYJV-TYYBGVCCSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/0005—Components or details
- B05B11/0089—Dispensing tubes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1001—Piston pumps
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mechanical Engineering (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本实用新型的供装填干细胞活性胜肽药剂的喉用喷雾器,至少包含有:按压体、固定套、容器以及加压组件,该容器内装填有干细胞活性胜肽药剂,利用按压体控制加压组件,可汲取容器内的干细胞活性胜肽药剂以通过喷嘴进而雾化喷出,本实用新型适用于由喉咙黏膜组织来传输胜肽类活性成分,藉由喉用喷雾器所构成的物理性障壁,隔离外界的水分、空气和光线,使得胜肽类活性成分在保存期间维持其活性和稳定性。
Description
技术领域
本实用新型有关一种喉用喷雾器,尤指一种供装填干细胞活性胜肽药剂的喉用喷雾器。
背景技术
身体内的大部分组成,往往都是已经成熟分化完全的细胞,例如皮肤细胞、肝脏细胞,或是口腔细胞。这些细胞的特性,在没有任何的外力刺激或是突变下,通常被认为细胞的命运已经决定,不会再转变为其他细胞,这样的细胞通称为“体细胞”(somatic cell)。而干细胞则是和这些已经分化完成的体细胞有显著的差异性。干细胞指尚未完全分化,而具有“分化能力”(differentiation),并可分化成两种以上成熟细胞的原始细胞,可以在身体内受到各式各样的刺激,来改变细胞命运,分化成特定的细胞。
以分化能力将干细胞分类,可分为全能干细胞(totipotent stem cell)、万能干细胞(pluripotent stem cell)、多能干细胞(multipotent stem cell)及单能干细胞(unipotent stem cell);另依干细胞来源区分,则可分为胚胎干细胞(embryonic stemcell)、成体干细胞(somatic stem cell)及诱导型万能干细胞(induced pluripotentstem cell;iPSC)。其中,人类胚胎干细胞属于万能干细胞,来自于未着床前囊胚时期的内细胞团块,具有万能性而可分化为各种成体细胞;另者,诱导型万能干细胞则以强迫表现(enforced expression)操作的方式,将特定基因或蛋白质导入已分化的体细胞,使该体细胞被重新程序化(reprogrammed)而成为类似胚胎干细胞者。根据医学研究认为干细胞有用于修复组织或器官的潜力,能应用于治疗癌症、修补器官、新药开发、制造人造器官等多种应用,能改变人类对疾病的应对方法。
以往,药理活性胜肽或蛋白质等药物的投药,主要是对静脉内或皮下以注射方式进行投药。然而,藉注射的药物投药,对患者而言往往造成很大的精神上负担或是肉体痛苦,或有由患者自行投药困难等不便的问题。因此,近年来,以经由肺黏膜、鼻黏膜、口腔黏膜、喉咙黏膜、***黏膜、胃黏膜、消化管黏膜等黏膜进行投药的途径作为注射以外的药物投药途径已开始受到注目。
因此,本实用新型技术领域亟需一种新而有用的喉用喷雾器,其适用于经由喉咙黏膜组织,进行胜肽类活性成分的传输,以便藉由喉用喷雾器所构成的物理性障壁,隔离外界的水分、空气和光线,使得胜肽类活性成分在保存期期间维持其活性和稳定性。
实用新型内容
本实用新型所解决的技术问题即在提供一种喉用喷雾器,尤指一种供装填干细胞活性胜肽药剂的喉用喷雾器。
本实用新型所采用的技术手段如下所述。
本实用新型的喉用喷雾器至少包含有:具有长型喷嘴的按压体、固定套、容器以及加压组件,按压体具有一中空架构的套接管,其内部并横向配置一喷液管,该喷液管的一端朝该按压体的下段部呈直角弯折形成一第一喷流孔,该喷液管的另一端则延伸至该套接管的外周面,并横向接设有一突出于按压体外的长型喷嘴,该长型喷嘴自由端则形成有一第二喷流孔;固定套上段部呈一罩口向上承接该按压体,且中心设一贯穿的穿孔供该喷液管的一端穿置其中;容器对应套合固定于该固定套的下段部,该容器内装填有干细胞活性胜肽药剂;加压组件装设于该固定套的穿孔处,设有一汲吸管件,该汲吸管件一端深入于该容器底部,另一端则露出于该固定套的套口,并以可拆卸方式组接于该喷液管的一端,利用按压体控制加压组件,可汲取容器内的干细胞活性胜肽药剂以通过喷嘴进而雾化喷出。
依据上述技术特征,所述干细胞活性胜肽药剂是源自于干细胞的胞外分泌物。
依据上述技术特征,所述干细胞是采自于胚胎的胚胎干细胞,或是采自于生物体的骨髓、脐带血、周边血或脂肪组织的成体干细胞。
依据上述技术特征,所述干细胞是藉由将特定基因或是特定基因产物导入体细胞内使的重新具有分化能力的诱导性多功能干细胞(induced pluripotent stem cells)。
依据上述技术特征,所述干细胞是采自于骨髓、脐带血、脂肪组织、牙髓腔、牙周韧带或关节液的间充质干细胞(mesenchymal stem cells,简称MSC)。
依据上述技术特征,所述加压组件的汲吸管件配置有一汲吸管、容置管以及吸管,该汲吸管底端穿设一第一弹簧后接设一锥形套,该锥形套底部穿组一压杆,该压杆尾端再设置一第二弹簧,该第二弹簧另端设置一滚珠,该容置管供将前述的汲吸管、第一弹簧、锥形套、压杆、第二弹簧及滚珠由上而下依序容置于管内,又于该容置管底端套接于该吸管。
依据上述技术特征,所述汲吸管上段部突出于该固定套的上段部。
依据上述技术特征,所述按压体以可拆装方式固定于该固定套的上段部。
依据上述技术特征,所述固定套进一步装设有一保护盖,该保护盖覆盖该汲吸管。
本实用新型所产生的技术效果:本实用新型的喉用喷雾器不但对于胜肽类活性成分提供充分的保护,并兼顾胜肽类活性成分的高传输效率,且相较于其他投药途径,经由鼻黏膜投药具有快速吸收、高生体可用率和快速发生效果等优势。
附图说明
图1所示为本实用新型中喉用喷雾器的结构立体图。
图2所示为本实用新型中喉用喷雾器的结构剖视图。
图3所示为本实用新型中喉用喷雾器的结构分解图。
图4所示为本实用新型中喉用喷雾器的使用示意图。
图5所示为本实用新型中喉用喷雾器的另一结构立体图。
图号说明:
喉用喷雾器1
按压体10
套接管11
长型喷嘴12
第二喷流孔121
喷液管13
第一喷流孔131
固定套20
罩口21
穿孔22
容器30
加压组件40
汲吸管件400
汲吸管41
第二组装部411
第一弹簧42
锥形套43
压杆44
第二弹簧45
滚珠46
容置管47
吸管48
干细胞活性胜肽药剂50
保护盖60。
具体实施方式
请参阅图1所示为本实用新型中喉用喷雾器的结构立体图所示,图2所示为本实用新型中喉用喷雾器的结构剖视图所示。首先,本实用新型的喉用喷雾器1至少包含:按压体10、固定套20、容器30以及加压组件40,其中:按压体10其具有一中空架构的套接管11,其内部并横向配置一喷液管13,该喷液管13的一端朝该按压体10的下段部呈直角弯折形成一第一喷流孔131,该喷液管13的另一端则延伸至该套接管11的外周面,并横向接设有一突出于按压体10外的长型喷嘴12,该长型喷嘴12的自由端则形成有一第二喷流孔121,其中喷液管13以及长型喷嘴12与套接管11内部则形成相通状态。
固定套20其上段部呈一罩口21向上承接按压体10,且中心设一贯穿的穿孔22供该喷液管13的一端穿置其中。
容器30对应套合固定于该固定套20的下段部,该容器30内装填有干细胞活性胜肽药剂50。
加压组件40装设于该固定套20的穿孔22处,该加压组件40设有一汲吸管件400,该汲吸管件400一端深入于该容器30底部,另一端则露出于该固定套20上段部的套口21,并以可拆卸方式组接于该喷液管13的一端的第一喷流孔131处,该汲吸管件可受该套接管12的控制而汲取该容器30内的干细胞活性胜肽药剂以通过该喷嘴进而雾化喷出;在一个优选具体实施方案中,请同时参阅第3图所示,加压组件40的汲吸管件400由一汲吸管41、容置管47以及吸管48所构成,汲吸管41上段部突出于该固定套20的上段部,汲吸管41底端穿设一第一弹簧42后接设一锥形套43,锥形套43底部穿组一压杆44,压杆44尾端再设置一第二弹簧45,第二弹簧45另端设置一滚珠46,容置管47供将前述的汲吸管41、第一弹簧42、锥形套43、压杆44、第二弹簧45及滚珠46由上而下依序容置于管内,又于容置管47底端套接于该吸管48。当然,本案中加压组件亦可以仅设置有一弹簧,或者为本实用新型所属技术领域中具有通常知识者所熟知的喷雾瓶内所使用的结构。
当使用者使用时,请同时参阅第4图所示,使用者藉由长型喷嘴12可深入咽喉处,再以手部施力于按压体10,使容器30内空气瞬间往喷嘴11喷出,同时因虹吸的效应,将按压体10内的干细胞活性胜肽药剂一起跟空气从吸管48进入容置管47内,此时,因第二弹簧45的伸缩弹力的关系,令压杆43底部压住滚珠45,使滚珠46堵住容置管47的口洞,且使压杆44与锥形套43产生缝隙空间,使容置管47内的干细胞活性胜肽药剂顺着缝隙空间朝压杆44外缘渗入汲吸管41内,再经由汲吸管41将药剂跟空气从喷嘴11的第二喷流孔121喷出,当放开按压体10时,容器30内的干细胞活性胜肽药剂再次跟空气从吸管48又进入容置管47内。
另外,按压体以可拆卸方式固定于该固定套20上段部的套口21,如图3及图4所示的实施例中,可将喷液管13以及汲吸管41设计为可相互套接的构型结构,例如喷液管13的内径略大于汲吸管41的外径(如图3的实施例所示),或者汲吸管41的内径略大于喷液管13的外径(图未示),利用喷液管13以及汲吸管41相互套接卡合的作用,可让按压体10以可拆装方式固定于该固定套20的上段部;而该固定套20进一步装设有一保护盖60,当按压体10拆卸后,该保护盖60可固定于该固定套20并覆盖该汲吸管41外,用以封闭该汲吸管41以对容器30内的干细胞活性胜肽药剂50提供更佳的保护效果。
本案说明书中所使用的“干细胞活性胜肽药剂”此用语意指由干细胞衍生而来且其本身或其代谢产物在医药或营养上具有活性的胜肽类药剂材料,其可以包含全长蛋白质及其胜肽片段、彼等的代谢产物或降解产物,以及彼等的组合物和混合物。在较佳的具体例中,本案干细胞活性胜肽药剂是源自于干细胞的胞外分泌物。所述干细胞可以是全能(totipotent)、万能(pluripotent)、多能干细胞(multipotent)或单能(unipotent)干细胞。就干细胞的来源来说,它们可以是采自于胚胎的胚胎干细胞,或是采自于例如生物体的骨髓、脐带血、周边血或脂肪组织的成体干细胞,甚至是藉由将特定基因或是特定基因产物导入体细胞内使的重新具有分化能力的诱导性多功能干细胞(induced pluripotent stemcells)。在较佳的具体例中,所述干细胞是多能干细胞,例如采自于骨髓、脐带血、脂肪组织、牙髓腔、牙周韧带或关节液的间充质干细胞(mesenchymal stem cells,简称MSC)。
所述胞外分泌物通常是藉由从组织中分离出干细胞,随后在适当的培养基中将干细胞培育一段时间,再收集上清液而得。举例而言,在由牙髓间充质干细胞取得胞外分泌物的具体例中,首先通过外科手术获取牙髓组织,接着使用胶原蛋白酶消化骨髓组织,将离心后所沉淀出来的细胞团利用磷酸盐缓冲液进行清洗,再将细胞置入培养基中培养并且去除其他细胞以收集间充质干细胞。随后将所收集到的间充质干细胞培养于不含牛血清的培养基中,历时24至48小时。藉由离心或过滤去除细胞和固体杂质后,所收集到的上清液即为间充质干细胞的胞外分泌物。目前许多的研究已经发现,由间充质干细胞所衍生出来的胞外分泌物含有能够促进细胞再生和免疫调节的活性胜肽。可以进一步将上述含有活性胜肽的胞外分泌物加以纯化。这些纯化手段及作业条件为本实用新型所属技术领域中具有通常知识者所熟知,这些手段包括但不限于过滤、盐析、萃取、透析、尺寸区别层析、厌水交互作用层析、离子交换层析以及亲和层析。因此,本案所称干细胞活性胜肽粉末可以呈现出实质上纯质的单一种胜肽、由多种胜肽所构成的混合物、经部分单离的含胜肽馏分(fractions)、含胜肽粗萃物,以及彼等的组合等形式。视本案干细胞活性胜肽药剂所欲制成的剂型而定,上述干细胞分泌物或其纯化产物可呈液体形式,也可以进一步经过习用冷冻干燥制程而制作成为冻干粉末(lyophilized powder)形式。
本案中干细胞活性胜肽粉末或其代谢产物可以在医药或营养上展现出对于接受的个体有利的活性。此处所称的“个体”意欲涵盖人类或非人类脊椎动物,例如非人类哺乳动物。非人类哺乳动物包括家畜动物、陪伴动物、实验室动物和非人灵长类动物。非人类个体亦包括而不限于马、牛、猪、山羊、狗、猫、小鼠、大鼠、天竺鼠、沙鼠、仓鼠、水貂、兔和鱼。较佳者为人类,尤其是患有特定疾病而需要给予干细胞活性胜肽做为治疗剂、辅助性药品或营养补充品的人类病患,抑或是适合给予干细胞活性胜肽来保养身体、预防疾病或补充营养的健康人类。举例而言,本案干细胞活性胜肽粉末可以应用于改善特定疾病的症状,针对体内造成特定疾病的一连串生物反应进行抑制作用,抑或是增强或调节体免疫反应,以达到降低致病因子、阻断致病反应、中和致病物质的生理化学过程,从而产生减轻、缓和或消除疾病的效果。
本案中干细胞活性胜肽药剂中通常也选择性地掺合有药学或营养学上可接受的赋形剂、界面活性剂、崩散剂、黏结剂、稀释剂、润滑剂、安定剂、抗氧化剂、矫味剂、甘味剂、染色剂、吸收促进剂、增塑剂等辅助剂。此处所称“药学或营养学上可接受”意指这些辅助剂对于给予的个体不具有毒性、刺激性、热原性、抗原性及溶血性,而且无实质的药理活性,也不会妨碍干细胞活性胜肽粉末的有益效果的发挥。这些辅助剂皆为本实用新型所属技术领域中具有通常知识者所熟悉。举例而言,所述赋形剂可以选自于麦芽糖糊精、胶态二氧化硅、淀粉、淀粉糖浆和α-乳糖。所述稀释剂可以选自于乳糖、淀粉、甘露醇、山梨醇、葡萄糖、磷酸三钙、磷酸钙、羟丙甲基纤维素、羟丙甲基纤维素醋酸硬脂酸酯、蔗糖、硫酸钙二水合物、乳酸钙三水合物、甘胺酸、高岭土等。所述润滑剂可以选自于硬脂酸、氢氧化钙、滑石、硬脂基反丁烯二酸钠、氢化植物油、高碳脂肪酸及其碱金属与碱土金属盐、甘油、滑石、蜡、硼酸、苯甲酸钠、醋酸钠、氯化钠、白胺酸、聚乙二醇、甲氧基聚乙二醇、油酸钠、苯甲酸钠、正廿二烷酸甘油基酯、月桂基硫酸钠,胶态二氧化硅、玉米淀粉等。
本案将干细胞活性胜肽药剂装填于容器中用于喉用喷雾器,不但对于胜肽类活性成分提供充分的保护,并兼顾胜肽类活性成分的高传输效率,且相较于其他投药途径,经由鼻黏膜投药可直接渗透到微血管而进入全身循环统,不经过肠胃道,因而得以避免肠胃道内部环境和酵素对于胜肽的破坏,故具有快速吸收、高生体可用率和快速发生效果等优势。
Claims (6)
1.一种供装填干细胞活性胜肽药剂的喉用喷雾器,其特征在于,至少包含:
一按压体,其具有一中空架构的套接管,其内部并横向配置一喷液管,该喷液管的一端朝该按压体的下段部呈直角弯折形成一第一喷流孔,该喷液管的另一端则延伸至该套接管的外周面,并横向接设有一突出于按压体外的长型喷嘴,该长型喷嘴自由端则形成有一第二喷流孔;
一固定套,其上段部呈一罩口向上承接该按压体,且中心设一贯穿的穿孔供该喷液管的一端穿置其中;
一容器,对应套合固定于该固定套的下段部,该容器内装填有干细胞活性胜肽药剂;以及
一加压组件,装设于该固定套的穿孔处,设有一汲吸管件,该汲吸管件一端深入于该容器底部,另一端则露出于该固定套的套口,并以可拆卸方式组接于该喷液管的一端,该汲吸管件可受该套接管的控制而汲取该容器内的干细胞活性胜肽药剂以通过该喷嘴进而雾化喷出。
2.如权利要求1所述的供装填干细胞活性胜肽药剂的喉用喷雾器,其特征在于,该加压组件的汲吸管件配置有一汲吸管、容置管以及吸管,该汲吸管底端穿设一第一弹簧后接设一锥形套,该锥形套底部穿组一压杆,该压杆尾端设置一第二弹簧,该第二弹簧另端设置一滚珠,该容置管供将前述的汲吸管、第一弹簧、锥形套、压杆、第二弹簧及滚珠由上而下依序容置于管内,又于该容置管底端套接于该吸管。
3.如权利要求2所述的供装填干细胞活性胜肽药剂的喉用喷雾器,其特征在于,该汲吸管上段部突出于该固定套上段部的套口。
4.如权利要求3所述的供装填干细胞活性胜肽药剂的喉用喷雾器,其特征在于,该固定套装设有一保护盖,该保护盖覆盖该汲吸管。
5.如权利要求3所述的供装填干细胞活性胜肽药剂的喉用喷雾器,其特征在于,该喷液管的内径大于该汲吸管的外径。
6.如权利要求3所述的供装填干细胞活性胜肽药剂的喉用喷雾器,其特征在于,该汲吸管的内径大于该喷液管的外径。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106208997U TWM553196U (zh) | 2017-06-21 | 2017-06-21 | 供裝填幹細胞活性胜肽藥劑之喉用噴霧器 |
TW106208997 | 2017-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN209004926U true CN209004926U (zh) | 2019-06-21 |
Family
ID=61229240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201721888089.5U Active CN209004926U (zh) | 2017-06-21 | 2017-12-28 | 供装填干细胞活性胜肽药剂的喉用喷雾器 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN209004926U (zh) |
DE (1) | DE202018100276U1 (zh) |
TW (1) | TWM553196U (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11944742B1 (en) * | 2023-06-08 | 2024-04-02 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to an animal |
-
2017
- 2017-06-21 TW TW106208997U patent/TWM553196U/zh not_active IP Right Cessation
- 2017-12-28 CN CN201721888089.5U patent/CN209004926U/zh active Active
-
2018
- 2018-01-18 DE DE202018100276.7U patent/DE202018100276U1/de active Active
Also Published As
Publication number | Publication date |
---|---|
TWM553196U (zh) | 2017-12-21 |
DE202018100276U1 (de) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101152568A (zh) | 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂 | |
CN209004926U (zh) | 供装填干细胞活性胜肽药剂的喉用喷雾器 | |
CN101646429A (zh) | 镇定剂及功能性食品 | |
CN101343317A (zh) | 脑肽及其制备方法及其用途 | |
CN209075739U (zh) | 供装填干细胞活性胜肽药剂的鼻用喷雾器 | |
CN101134050A (zh) | 增强机体免疫功能药物组合物及其制备工艺 | |
CN107446018A (zh) | 促进伤口愈合的肽及其应用 | |
JP5819209B2 (ja) | 幹細胞から褐色脂肪細胞への分化促進剤 | |
RU2441660C1 (ru) | Способ лечения субклинического мастита у лактирующих коров | |
CN101156849B (zh) | 一种促牙周再生的苯妥英钠缓释凝胶及其制备方法与应用 | |
CN111514279A (zh) | 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用 | |
CN213883595U (zh) | 一种儿科口腔清洁护理装置 | |
CN1323662C (zh) | 含有氨溴索和厄多司坦或乙酰半胱氨酸的药物组合物及其应用 | |
CN209137414U (zh) | 微脂体结构 | |
CN207928405U (zh) | 分段给药的吞咽训练笔 | |
KR101893339B1 (ko) | Gdf11을 포함하는 조성물 및 그의 용도 | |
CN113856011B (zh) | 通过气道内滴人间充质干细胞治疗肺部纤维化的装置 | |
CN215606804U (zh) | 一种药物冰球口腔刺激器 | |
JP7203033B2 (ja) | 運動系の疾患の治療のために有用な組成物 | |
WO2023218804A1 (ja) | 膵機能活性化剤、抗老化剤、2型糖尿病の治療薬または予防薬、医薬品、化粧品および食品または飲料 | |
CN215308458U (zh) | 一种用于老年科辅助喂药设备 | |
CN1879711A (zh) | 一种治疗胃病的中药组合物及其制备方法和质量控制方法 | |
CN207950205U (zh) | 一种作为眼部用药的纳米药物缓释载体 | |
CN2757847Y (zh) | 一种新型妇科送药器 | |
CN102085360B (zh) | 原料含有水蛭素的药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230104 Address after: 15 / F, 8 / F, No. 10, Section 1, Chongqing South Road, Zhongzheng District, Taibei City, Taiwan, China Patentee after: You'an Cell Biomedical Technology Co.,Ltd. Address before: No. 8, 214 Lane, Section 2, East Nanjing Road, Zhongshan District, Taipei City, Taiwan, China Patentee before: Caire Medical-Biotechnology International Co. |